Stephens Inc. AR Decreases Position in Align Technology, Inc. $ALGN

Stephens Inc. AR decreased its stake in Align Technology, Inc. (NASDAQ:ALGN) by 24.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,359 shares of the medical equipment provider’s stock after selling 762 shares during the period. Stephens Inc. AR’s holdings in Align Technology were worth $447,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of ALGN. Wealth Enhancement Advisory Services LLC boosted its position in shares of Align Technology by 44.3% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 9,380 shares of the medical equipment provider’s stock worth $1,490,000 after buying an additional 2,881 shares during the period. Janney Montgomery Scott LLC boosted its position in shares of Align Technology by 48.9% in the first quarter. Janney Montgomery Scott LLC now owns 10,120 shares of the medical equipment provider’s stock worth $1,608,000 after buying an additional 3,325 shares during the period. Oppenheimer & Co. Inc. boosted its position in shares of Align Technology by 2.3% in the first quarter. Oppenheimer & Co. Inc. now owns 10,570 shares of the medical equipment provider’s stock worth $1,679,000 after buying an additional 241 shares during the period. Asset Management One Co. Ltd. boosted its holdings in Align Technology by 14.5% in the first quarter. Asset Management One Co. Ltd. now owns 31,624 shares of the medical equipment provider’s stock valued at $5,024,000 after purchasing an additional 4,009 shares during the last quarter. Finally, Robeco Institutional Asset Management B.V. boosted its holdings in Align Technology by 69.7% in the first quarter. Robeco Institutional Asset Management B.V. now owns 37,336 shares of the medical equipment provider’s stock valued at $5,931,000 after purchasing an additional 15,329 shares during the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.

Insider Buying and Selling at Align Technology

In related news, CEO Joseph M. Hogan purchased 7,576 shares of the company’s stock in a transaction dated Friday, August 1st. The shares were acquired at an average cost of $131.49 per share, for a total transaction of $996,168.24. Following the transaction, the chief executive officer owned 184,945 shares of the company’s stock, valued at $24,318,418.05. This trade represents a 4.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.66% of the company’s stock.

Align Technology Stock Down 0.6%

NASDAQ:ALGN opened at $135.21 on Friday. The business’s 50 day moving average is $134.14 and its two-hundred day moving average is $162.80. The company has a market cap of $9.80 billion, a PE ratio of 22.80, a P/E/G ratio of 1.53 and a beta of 1.70. Align Technology, Inc. has a 52 week low of $122.00 and a 52 week high of $246.19.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.08). The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1.06 billion. Align Technology had a return on equity of 13.36% and a net margin of 11.04%.The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.41 earnings per share. Align Technology has set its Q3 2025 guidance at EPS. As a group, sell-side analysts expect that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology announced that its board has approved a stock repurchase plan on Tuesday, August 5th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 2% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Analyst Ratings Changes

ALGN has been the subject of a number of analyst reports. Mizuho reduced their price target on Align Technology from $210.00 to $170.00 and set an “outperform” rating for the company in a report on Monday, October 13th. Zacks Research raised Align Technology from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 30th. Jefferies Financial Group reissued a “hold” rating and issued a $140.00 price target (down previously from $215.00) on shares of Align Technology in a report on Friday, October 10th. Wells Fargo & Company reduced their price target on Align Technology from $246.00 to $199.00 and set an “overweight” rating for the company in a report on Thursday, July 31st. Finally, UBS Group reduced their target price on Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Thursday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $173.09.

Align Technology Company Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.